Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification

Junko Tanizaki, Isamu Okamoto, Ken Takezawa, Sayaka Tsukioka, Junji Uchida, Mamoru Kiniwa, Masahiro Fukuoka, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome. Combination therapies with HER2-targeting agents and cytotoxic agents are considered a potential therapeutic option for gastric cancer with HER2 amplification. We have now investigated the effects of combination treatment with the oral fluoropyrimidine S-1 and the HER2-targeting agents lapatinib or trastuzumab in gastric cancer cells with or without HER2 amplification. We used 5-fluorouracil (5FU) instead of S-1 for in vitro experiments, given that tegafur, a component of S-1, is metabolized to 5FU in the liver. The combination of 5FU and HER2-targeting agents synergistically inhibited cell proliferation and exhibited an enhanced proapoptotic effect in gastric cancer cells with HER2 amplification, but not in those without it. Lapatinib or trastuzumab also induced downregulation of thymidylate synthase (TS) expression and activity only in cells with HER2 amplification. The combination of 5FU and TS depletion by RNA interference also exhibited an enhanced proapoptotic effect in cells with HER2 amplification. These observations thus suggest that lapatinib-induced or trastuzumab-induced downregulation of TS is responsible, at least in part, for the synergistic antitumor effect of combined treatment with 5FU and HER2-targeting agents. The antitumor effect of the combination of S-1 and HER2-targeting agents in vivo was also greater than that of either drug alone. Our preclinical findings thus indicate that the combination of S-1 and HER2-targeting agents is a promising treatment option for gastric cancer with HER2 amplification.

Original languageEnglish
Pages (from-to)1198-1207
Number of pages10
JournalMolecular Cancer Therapeutics
Volume9
Issue number5
DOIs
Publication statusPublished - May 1 2010
Externally publishedYes

Fingerprint

Stomach Neoplasms
Fluorouracil
Thymidylate Synthase
human ERBB2 protein
Down-Regulation
Tegafur
Cytotoxins
RNA Interference
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. / Tanizaki, Junko; Okamoto, Isamu; Takezawa, Ken; Tsukioka, Sayaka; Uchida, Junji; Kiniwa, Mamoru; Fukuoka, Masahiro; Nakagawa, Kazuhiko.

In: Molecular Cancer Therapeutics, Vol. 9, No. 5, 01.05.2010, p. 1198-1207.

Research output: Contribution to journalArticle

Tanizaki, J, Okamoto, I, Takezawa, K, Tsukioka, S, Uchida, J, Kiniwa, M, Fukuoka, M & Nakagawa, K 2010, 'Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification', Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1198-1207. https://doi.org/10.1158/1535-7163.MCT-10-0045
Tanizaki, Junko ; Okamoto, Isamu ; Takezawa, Ken ; Tsukioka, Sayaka ; Uchida, Junji ; Kiniwa, Mamoru ; Fukuoka, Masahiro ; Nakagawa, Kazuhiko. / Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 5. pp. 1198-1207.
@article{fa089b7dcbf34628b7d44644fa63376d,
title = "Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification",
abstract = "Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20{\%} to 30{\%} of gastric cancers and is associated with a poor outcome. Combination therapies with HER2-targeting agents and cytotoxic agents are considered a potential therapeutic option for gastric cancer with HER2 amplification. We have now investigated the effects of combination treatment with the oral fluoropyrimidine S-1 and the HER2-targeting agents lapatinib or trastuzumab in gastric cancer cells with or without HER2 amplification. We used 5-fluorouracil (5FU) instead of S-1 for in vitro experiments, given that tegafur, a component of S-1, is metabolized to 5FU in the liver. The combination of 5FU and HER2-targeting agents synergistically inhibited cell proliferation and exhibited an enhanced proapoptotic effect in gastric cancer cells with HER2 amplification, but not in those without it. Lapatinib or trastuzumab also induced downregulation of thymidylate synthase (TS) expression and activity only in cells with HER2 amplification. The combination of 5FU and TS depletion by RNA interference also exhibited an enhanced proapoptotic effect in cells with HER2 amplification. These observations thus suggest that lapatinib-induced or trastuzumab-induced downregulation of TS is responsible, at least in part, for the synergistic antitumor effect of combined treatment with 5FU and HER2-targeting agents. The antitumor effect of the combination of S-1 and HER2-targeting agents in vivo was also greater than that of either drug alone. Our preclinical findings thus indicate that the combination of S-1 and HER2-targeting agents is a promising treatment option for gastric cancer with HER2 amplification.",
author = "Junko Tanizaki and Isamu Okamoto and Ken Takezawa and Sayaka Tsukioka and Junji Uchida and Mamoru Kiniwa and Masahiro Fukuoka and Kazuhiko Nakagawa",
year = "2010",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-10-0045",
language = "English",
volume = "9",
pages = "1198--1207",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification

AU - Tanizaki, Junko

AU - Okamoto, Isamu

AU - Takezawa, Ken

AU - Tsukioka, Sayaka

AU - Uchida, Junji

AU - Kiniwa, Mamoru

AU - Fukuoka, Masahiro

AU - Nakagawa, Kazuhiko

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome. Combination therapies with HER2-targeting agents and cytotoxic agents are considered a potential therapeutic option for gastric cancer with HER2 amplification. We have now investigated the effects of combination treatment with the oral fluoropyrimidine S-1 and the HER2-targeting agents lapatinib or trastuzumab in gastric cancer cells with or without HER2 amplification. We used 5-fluorouracil (5FU) instead of S-1 for in vitro experiments, given that tegafur, a component of S-1, is metabolized to 5FU in the liver. The combination of 5FU and HER2-targeting agents synergistically inhibited cell proliferation and exhibited an enhanced proapoptotic effect in gastric cancer cells with HER2 amplification, but not in those without it. Lapatinib or trastuzumab also induced downregulation of thymidylate synthase (TS) expression and activity only in cells with HER2 amplification. The combination of 5FU and TS depletion by RNA interference also exhibited an enhanced proapoptotic effect in cells with HER2 amplification. These observations thus suggest that lapatinib-induced or trastuzumab-induced downregulation of TS is responsible, at least in part, for the synergistic antitumor effect of combined treatment with 5FU and HER2-targeting agents. The antitumor effect of the combination of S-1 and HER2-targeting agents in vivo was also greater than that of either drug alone. Our preclinical findings thus indicate that the combination of S-1 and HER2-targeting agents is a promising treatment option for gastric cancer with HER2 amplification.

AB - Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome. Combination therapies with HER2-targeting agents and cytotoxic agents are considered a potential therapeutic option for gastric cancer with HER2 amplification. We have now investigated the effects of combination treatment with the oral fluoropyrimidine S-1 and the HER2-targeting agents lapatinib or trastuzumab in gastric cancer cells with or without HER2 amplification. We used 5-fluorouracil (5FU) instead of S-1 for in vitro experiments, given that tegafur, a component of S-1, is metabolized to 5FU in the liver. The combination of 5FU and HER2-targeting agents synergistically inhibited cell proliferation and exhibited an enhanced proapoptotic effect in gastric cancer cells with HER2 amplification, but not in those without it. Lapatinib or trastuzumab also induced downregulation of thymidylate synthase (TS) expression and activity only in cells with HER2 amplification. The combination of 5FU and TS depletion by RNA interference also exhibited an enhanced proapoptotic effect in cells with HER2 amplification. These observations thus suggest that lapatinib-induced or trastuzumab-induced downregulation of TS is responsible, at least in part, for the synergistic antitumor effect of combined treatment with 5FU and HER2-targeting agents. The antitumor effect of the combination of S-1 and HER2-targeting agents in vivo was also greater than that of either drug alone. Our preclinical findings thus indicate that the combination of S-1 and HER2-targeting agents is a promising treatment option for gastric cancer with HER2 amplification.

UR - http://www.scopus.com/inward/record.url?scp=77952201843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952201843&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0045

DO - 10.1158/1535-7163.MCT-10-0045

M3 - Article

C2 - 20424000

AN - SCOPUS:77952201843

VL - 9

SP - 1198

EP - 1207

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -